MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Market Cap	$70.63M	P/E Ratio	N/A
52W High	$2.48	52W Low	$1.13
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-3.1%	52W Position	22.2%
Overall Score	63	Value Score	60
Quality Score	--	Technical Score	66

EPS Current Est	$-0.3	EPS Next Est	$-0.33
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MNOV	$1.43	+0.70%	57.21K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MNOV	$1.43	+0.7%	57.21K
3
4
5
6

MNOV

MNOV

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get MediciNova Inc. Data in Excel

Get MediciNova Inc. Data in Excel